Home Drug IndexClinical Monograph

Nipradilol Uses, Dosage, Side Effects & Benefits | DrugsAtlas

Authoritative Clinical Reference

DRUG NAME: Nipradilol

Therapeutic Class: Antiglaucoma Agent

Subclass: Non-selective Beta-blocker with α1-blocking and Nitric Oxide Donating Properties

Specialty: Ophthalmology

Schedule (India): Schedule H

Route(s): Ophthalmic

Formulations Available in India:
• Eye drops: 0.5% w/v

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

Indication	Starting Dose	Titration	Maintenance Dose	Maximum Dose	Clinical Notes
Primary Open-angle Glaucoma	1 drop of 0.5% in affected eye(s) twice daily	Not applicable; assess response at 2–4 weeks	1 drop twice daily	1 drop twice daily per eye	Onset of IOP reduction within 1–2 hours; maximum effect may require several weeks
Ocular Hypertension	1 drop of 0.5% in affected eye(s) twice daily	Not applicable	1 drop twice daily	1 drop twice daily per eye	When combining with other topical antiglaucoma agents, maintain minimum 5–10 minute interval between instillations

Administration Notes:
• Apply nasolacrimal occlusion for 1–2 minutes post-instillation to reduce systemic absorption
• May be used as monotherapy or in combination with prostaglandin analogues, carbonic anhydrase inhibitors, or alpha-2 agonists

Secondary Indications — Adults (Off-label, if any)

Not applicable — No established off-label indications documented in Indian practice

PAEDIATRIC DOSING (Specialist Only)

Primary Indications:
• NOT APPROVED for routine paediatric use in India
• Safety and efficacy not established in children

Secondary Indications — Paediatrics (Off-label, if any):

Age Group	Indication	Dose	Notes
≥2 years	Developmental/juvenile glaucoma — OFF-LABEL	0.5% eye drops, 1 drop twice daily	Specialist only; paediatric ophthalmologist supervision mandatory
<2 years	Not recommended	—	Avoid unless exceptional circumstances under tertiary centre protocol

Safety Monitoring in Paediatrics:
• Monitor for systemic beta-blockade: bradycardia, bronchospasm, hypotension
• Heart rate assessment before and after initiation
• Nasolacrimal occlusion essential to minimize systemic absorption
• Not recommended below 18 years except under specialist supervision
• Limited Indian data available

RENAL ADJUSTMENT

• No dose adjustment required (topical ophthalmic administration with minimal systemic absorption)

HEPATIC ADJUSTMENT

Child-Pugh Class	Recommendation
Class A (Mild)	No dose adjustment required
Class B (Moderate)	No dose adjustment required
Class C (Severe)	Use with caution; limited data; monitor for systemic beta-blockade effects; specialist supervision advised

CONTRAINDICATIONS

• Known hypersensitivity to nipradilol or any formulation component
• Bronchial asthma or history of bronchial asthma
• Severe chronic obstructive pulmonary disease
• Sinus bradycardia (<50 beats per minute)
• Second-degree or third-degree atrioventricular block (without pacemaker)
• Sick sinus syndrome (without pacemaker)
• Decompensated heart failure
• Cardiogenic shock

CAUTIONS

• Controlled chronic obstructive pulmonary disease — risk of bronchospasm
• Diabetes mellitus — may mask hypoglycaemic symptoms (tachycardia, tremor)
• Thyrotoxicosis — may mask tachycardia
• Myasthenia gravis — potential worsening of muscle weakness
• Peripheral vascular disease and Raynaud’s phenomenon
• Corneal disease — may reduce corneal sensitivity with prolonged use
• History of ocular surgery — monitor IOP closely
• Concurrent systemic beta-blockers — additive effects
• First-degree AV block — monitor for progression
• Abrupt discontinuation — avoid; may cause rebound effects

PREGNANCY

Parameter	Details
Risk summary	Caution advised; no adequate human data; animal studies inconclusive
Preferred alternatives	Timolol (if beta-blocker required); brimonidine (safe in 2nd/3rd trimester)
When may be used	Only if benefit clearly justifies potential fetal risk; specialist supervision
Monitoring	Fetal growth; fetal heart rate if significant systemic absorption suspected; neonatal bradycardia and hypoglycaemia

LACTATION

Parameter	Details
Compatibility	Use with caution; likely minimal systemic absorption
Preferred alternatives	Timolol (more lactation safety data available)
Drug level in milk	Expected to be very low
Infant monitoring	Bradycardia, feeding difficulties, lethargy, inadequate weight gain
Administration advice	Apply nasolacrimal occlusion to reduce systemic absorption

ELDERLY

• Starting dose: 0.5% eye drops, 1 drop twice daily (standard adult dosing)
• Titration: Not applicable for topical formulation
• Special considerations:

Slower systemic clearance generally not a major concern with topical use
Monitor for systemic beta-blocking effects (bradycardia, hypotension) especially in frail patients
Assess concurrent medications for additive effects
Verify adequate manual dexterity for self-administration
Punctal occlusion technique particularly important

MAJOR DRUG INTERACTIONS

Interacting Drug	Effect	Recommendation
Systemic beta-blockers (atenolol, propranolol, metoprolol)	Additive beta-blockade; excessive bradycardia and hypotension	Avoid combination if possible; if essential, close monitoring of heart rate and blood pressure required
Verapamil, Diltiazem (systemic)	Increased risk of AV block and severe bradycardia	Avoid combination; specialist monitoring required if unavoidable
MAO inhibitors	Theoretical additive hypotensive effect	Avoid concurrent use
Clonidine	Risk of rebound hypertensive crisis on abrupt clonidine withdrawal	Taper clonidine gradually if discontinuing

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect	Recommendation
Other topical antiglaucoma agents	Additive IOP-lowering effect	May be used together; maintain 5–10 minute interval between instillations; monitor IOP
Insulin, sulfonylureas	Beta-blockade may mask hypoglycaemic symptoms	Monitor blood glucose; counsel diabetic patients
CNS depressants, sedatives	Potential additive bradycardic effect	Monitor heart rate
Digoxin	Additive bradycardia	Monitor heart rate and ECG

COMMON ADVERSE EFFECTS

• Ocular stinging or burning on instillation
• Eye irritation
• Blurred vision (transient)
• Photophobia
• Dry eye sensation
• Foreign body sensation
• Conjunctival hyperaemia
• Headache
• Fatigue (rare, from systemic absorption)

SERIOUS ADVERSE EFFECTS

• Symptomatic bradycardia — from systemic absorption; discontinue and refer
• Hypotension — from systemic absorption
• Bronchospasm — especially in predisposed individuals; discontinue immediately
• Corneal hypoesthesia — with prolonged use
• Severe allergic conjunctivitis or contact dermatitis — discontinue if suspected
• Severe ocular inflammation — discontinue and refer
• Syncope (rare)
• Worsening of heart failure (rare)

MONITORING REQUIREMENTS

Phase	Parameters
Baseline	Intraocular pressure, visual acuity, visual field assessment, optic nerve evaluation, heart rate and blood pressure (especially if cardiac comorbidities)
After initiation/dose change	IOP assessment at 2–4 weeks; evaluate tolerability and systemic effects
Long-term	IOP every 3–6 months; optic nerve status; corneal health; periodic heart rate and blood pressure (particularly in elderly or those on concurrent systemic beta-blockers)

BRANDS AVAILABLE IN INDIA

• Hyprol Eye Drops (Centaur Pharma)
• Nionex Eye Drops (Sunways India)

Note: Availability may be limited in certain regions; other generic brands under 0.5% strength may exist

PRICE RANGE (INR)

Formulation	Approximate Price
0.5% eye drops (5 mL)	₹60–100 per bottle

• Not included in NLEM; not under NPPA price control
• Availability variable across regions
• Private retail only

CLINICAL PEARLS

• Triple mechanism (β-blockade + α1-blockade + NO donation) provides enhanced IOP lowering compared to conventional beta-blockers
• Useful in patients intolerant to traditional beta-blockers due to reduced systemic bradycardic effects from NO-donating property
• Consider for poor responders to monotherapy — may offer additional IOP reduction without class change
• Nocturnal IOP lowering may be modest; assess nighttime control if relevant
• Punctal occlusion technique essential to minimize systemic absorption, especially in elderly or patients with cardiac disease
• Counsel patients not to touch dropper tip to eye surface to prevent contamination

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...